104
Participants
Start Date
October 15, 2019
Primary Completion Date
June 28, 2022
Study Completion Date
June 28, 2022
Psilocybin
The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
Niacin
The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
Set and Setting (SaS) Protocol
The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
New York University School of Medicine, New York
Johns Hopkins University, Baltimore
Emory University, Atlanta
Segal Trials, Lauderhill
University of Wisconsin - Madison, Madison
Great Lakes Clinical Trials, Chicago
Cedar Clinical Research, Draper
Pacific Neuroscience Institute, Santa Monica
University of California, San Francisco, San Francisco
Yale University, New Haven
Hassman Research Institute, Berlin
The Emmes Company, LLC
INDUSTRY
Usona Institute
OTHER